Oppenheimer & Co. Inc. bought a new stake in Charles River Laboratories (NYSE:CRL) during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 2,676 shares of the medical research company’s stock, valued at approximately $286,000.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its position in shares of Charles River Laboratories by 4.4% in the 4th quarter. Renaissance Technologies LLC now owns 1,398,700 shares of the medical research company’s stock valued at $153,088,000 after acquiring an additional 58,991 shares during the period. Geode Capital Management LLC increased its position in shares of Charles River Laboratories by 7.0% in the 4th quarter. Geode Capital Management LLC now owns 432,613 shares of the medical research company’s stock valued at $47,349,000 after acquiring an additional 28,456 shares during the period. BlackRock Inc. increased its position in shares of Charles River Laboratories by 0.8% in the 4th quarter. BlackRock Inc. now owns 4,034,318 shares of the medical research company’s stock valued at $441,557,000 after acquiring an additional 31,676 shares during the period. American International Group Inc. increased its position in shares of Charles River Laboratories by 0.8% in the 4th quarter. American International Group Inc. now owns 98,120 shares of the medical research company’s stock valued at $10,739,000 after acquiring an additional 753 shares during the period. Finally, Arizona State Retirement System increased its position in shares of Charles River Laboratories by 26.6% in the 4th quarter. Arizona State Retirement System now owns 34,090 shares of the medical research company’s stock valued at $3,731,000 after acquiring an additional 7,163 shares during the period. 99.97% of the stock is currently owned by hedge funds and other institutional investors.

In other news, insider David Ross Smith sold 945 shares of the firm’s stock in a transaction dated Tuesday, May 1st. The stock was sold at an average price of $104.23, for a total transaction of $98,497.35. Following the sale, the insider now directly owns 13,723 shares in the company, valued at approximately $1,430,348.29. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director George Massaro sold 1,218 shares of the firm’s stock in a transaction dated Monday, May 14th. The shares were sold at an average price of $107.19, for a total value of $130,557.42. Following the sale, the director now owns 15,055 shares in the company, valued at $1,613,745.45. The disclosure for this sale can be found here. Insiders have sold a total of 58,264 shares of company stock worth $6,390,411 over the last 90 days. Insiders own 2.10% of the company’s stock.

Shares of CRL opened at $105.00 on Friday. The stock has a market cap of $4.97 billion, a price-to-earnings ratio of 19.32, a P/E/G ratio of 1.31 and a beta of 0.69. The company has a debt-to-equity ratio of 0.99, a quick ratio of 1.78 and a current ratio of 2.07. Charles River Laboratories has a fifty-two week low of $102.98 and a fifty-two week high of $104.03.

Charles River Laboratories (NYSE:CRL) last announced its quarterly earnings results on Thursday, May 10th. The medical research company reported $1.38 earnings per share for the quarter, topping the consensus estimate of $1.26 by $0.12. The company had revenue of $493.97 million for the quarter, compared to the consensus estimate of $480.03 million. Charles River Laboratories had a return on equity of 24.96% and a net margin of 6.78%. The firm’s revenue for the quarter was up 10.8% compared to the same quarter last year. During the same period last year, the firm earned $1.29 EPS. analysts expect that Charles River Laboratories will post 5.84 EPS for the current year.

Several research firms recently issued reports on CRL. TheStreet downgraded Charles River Laboratories from an “a-” rating to a “c+” rating in a research report on Tuesday, February 13th. Zacks Investment Research downgraded Charles River Laboratories from a “buy” rating to a “hold” rating in a research report on Tuesday. ValuEngine downgraded Charles River Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, April 7th. JPMorgan Chase increased their price target on Charles River Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 14th. Finally, Mitsubishi UFJ Financial Group started coverage on Charles River Laboratories in a research report on Friday, April 20th. They set a “neutral” rating and a $115.00 price target on the stock. Nine research analysts have rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company. Charles River Laboratories has a consensus rating of “Buy” and an average price target of $115.86.

Charles River Laboratories Company Profile

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories (NYSE:CRL).

Institutional Ownership by Quarter for Charles River Laboratories (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.